Author | Deborah M. Stephens, DO

Articles

Proposed Algorithm for Managing Ibrutinib-Related Atrial Fibrillation

November 15, 2016

ByAlaina Vrontikis

Jessica Carey

Jeffrey A. Gilreath, PharmD

Ahmad Halwani, MD

Deborah M. Stephens, DO

John W. Sweetenham, MD

Although ibrutinib-related atrial fibrillation (IRAF) occurs in up to 11% of patients in clinical trials, these studies have rarely fully characterized bleeding events or risk factors for bleeding when ibrutinib is combined with anticoagulation. Furthermore, guidelines do not provide direction regarding the preferred anti-arrhythmic agent for IRAF.

Allogeneic Stem Cell Transplantation in Chronic Lymphocytic Leukemia: An Archaic Intervention or a Necessary Evil?

June 15, 2016

ByDeborah M. Stephens, DO

With novel therapeutic agents, is allogeneic HSCT an archaic intervention for patients with CLL?

Chronic Lymphocytic Leukemia With del(17p13.1): A Distinct Clinical Subtype Requiring Novel Treatment Approaches

November 15, 2012

ByDeborah M. Stephens, DO

John C. Byrd, MD

This review will discuss the pathophysiology associated with the del(17p13.1) interphase cytogenetic abnormality, the current generally poor outcomes in affected patients, currently approved therapeutic agents, and new agents now undergoing investigation.